Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
Magnetic resonance imaging of myelin using ultrashort Echo time (UTE) pulse sequences: Phantom, specimen, volunteer and multiple sclerosis patient studies.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Interferon-beta is a potent promoter of nerve growth factor production by astrocytes.
Induction of regulatory T-cells from memory T-cells is perturbed during acute exacerbation of multiple sclerosis.
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Sox10 Expression in Goldfish Retina and Optic Nerve Head in Controls and after the Application of Two Different Lesion Paradigms.
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
FDA product review for daclizumab
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Glatiramer acetate induced hepatotoxicity.
Biomarkers of disease activity in multiple sclerosis.
Vitamin D3 attenuates oxidative stress and cognitive deficits in a model of toxic demyelination.
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon.
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Morphogenesis of the demyelinating lesions in Baló's concentric sclerosis.
Treatment with retinoid X receptor agonist IRX4204 ameliorates experimental autoimmune encephalomyelitis.
Flupirtine in pain management: pharmacological properties and clinical use.
The role of global and regional gray matter volume decrease in multiple sclerosis.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Evidence for Mitoxantrone-induced Block of Inwardly Rectifying K Channels Expressed in the Osteoclast Precursor RAW 264.7 Cells Differentiated with Lipopolysaccharide.
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study.

Pages